602 related articles for article (PubMed ID: 24878386)
1. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
[TBL] [Abstract][Full Text] [Related]
2. Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of Ritonavir with Quercetin.
Dengale SJ; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Biopharm; 2015 Jan; 89():329-38. PubMed ID: 25542681
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
4. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
[TBL] [Abstract][Full Text] [Related]
5. Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin.
Beyer A; Grohganz H; Löbmann K; Rades T; Leopold CS
Eur J Pharm Biopharm; 2016 Dec; 109():140-148. PubMed ID: 27746228
[TBL] [Abstract][Full Text] [Related]
6. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
7. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
8. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K
Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246
[TBL] [Abstract][Full Text] [Related]
9. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation.
Chieng N; Aaltonen J; Saville D; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443
[TBL] [Abstract][Full Text] [Related]
10. Influence of variation in molar ratio on co-amorphous drug-amino acid systems.
Jensen KT; Larsen FH; Löbmann K; Rades T; Grohganz H
Eur J Pharm Biopharm; 2016 Oct; 107():32-9. PubMed ID: 27368747
[TBL] [Abstract][Full Text] [Related]
11. In situ amorphisation of indomethacin with Eudragit® E during dissolution.
Priemel PA; Laitinen R; Grohganz H; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1259-65. PubMed ID: 24056054
[TBL] [Abstract][Full Text] [Related]
12. [The development of co-amorphous drug systems].
Yao J; Shi NQ; Wang XL
Yao Xue Xue Bao; 2013 May; 48(5):648-54. PubMed ID: 23888685
[TBL] [Abstract][Full Text] [Related]
13. Spray drying of poorly soluble drugs from aqueous arginine solution.
Ojarinta R; Lerminiaux L; Laitinen R
Int J Pharm; 2017 Oct; 532(1):289-298. PubMed ID: 28890173
[TBL] [Abstract][Full Text] [Related]
14. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
Lenz E; Jensen KT; Blaabjerg LI; Knop K; Grohganz H; Löbmann K; Rades T; Kleinebudde P
Eur J Pharm Biopharm; 2015 Oct; 96():44-52. PubMed ID: 26197392
[TBL] [Abstract][Full Text] [Related]
15. Indomethacin co-amorphous drug-drug systems with improved solubility, supersaturation, dissolution rate and physical stability.
Fael H; Demirel AL
Int J Pharm; 2021 May; 600():120448. PubMed ID: 33675920
[TBL] [Abstract][Full Text] [Related]
16. Investigation of physical properties and stability of indomethacin-cimetidine and naproxen-cimetidine co-amorphous systems prepared by quench cooling, coprecipitation and ball milling.
Lim AW; Löbmann K; Grohganz H; Rades T; Chieng N
J Pharm Pharmacol; 2016 Jan; 68(1):36-45. PubMed ID: 26663364
[TBL] [Abstract][Full Text] [Related]
17. Exploring the physical stability of three nimesulide-indomethacin co-amorphous systems from the perspective of molecular aggregates.
Wang M; Liu S; Jia L; Zhang J; Du S; Gong J
Eur J Pharm Sci; 2020 Apr; 147():105294. PubMed ID: 32147483
[TBL] [Abstract][Full Text] [Related]
18. PH-induced nanosegregation of ritonavir to lyotropic liquid crystal of higher solubility than crystalline polymorphs.
Rodríguez-Spong B; Acciacca A; Fleisher D; Rodríguez-Hornedo N
Mol Pharm; 2008; 5(6):956-67. PubMed ID: 19434919
[TBL] [Abstract][Full Text] [Related]
19. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
Sun DD; Ju TC; Lee PI
Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
[TBL] [Abstract][Full Text] [Related]
20. Phase Behavior of Ritonavir Amorphous Solid Dispersions during Hydration and Dissolution.
Purohit HS; Taylor LS
Pharm Res; 2017 Dec; 34(12):2842-2861. PubMed ID: 28956218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
